“Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S43. doi:10.25251/skin.2.supp.43.